Jaguar Health Announces a Special Stock Dividend
Key Highlights
- ➤Special stock dividend declared for Jaguar (JAGX) common stockholders and eligible warrant holders
- ➤Record date October 13, 2026; payment date October 15, 2026
- ➤Each Preferred Stock share converts into five Common Stock shares November 2, 2026
- ➤Jaguar (JAGX) expects mid-2027 NDA filing for crofelemer in MVID
Expert Statements
Lisa Conte, Founder, President, and CEO of Jaguar Health
“Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we continue evaluation of strategic alternatives.”
Lisa Conte, Founder, President, and CEO of Jaguar Health
“We remain sharply focused on our ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support for rare intestinal failure diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) for crofelemer powder for oral solution.”
SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (link) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock"). The CUSIP number for the Preferred Stock is 47010C847.
Only persons who own shares of the Company's voting common stock (the "Common Stock"), or certain warrants to purchase Common Stock with dividend rights (the "Warrants") at the close of business on October 13, 2026 (the "Record Date") will be entitled to receive shares of the Preferred Stock. Each share of Preferred Stock will convert into five shares of Common Stock on November 2, 2026 (the "Conversion Date").
Get started
Create a free account to read the full story.